NTM-Pulmonary Infection - CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Skip to main content

Featured Authorities on MAC Lung Disease and NTM Pulmonary Infection

Antonino Catanzaro, MD

Antonino Catanzaro, MD

Professor of Medicine
Previously, Director, Tuberculosis Control

Division of Pulmonary, Critical Care, and Sleep Medicine

UC San Diego School of Medicine

San Diego, California

Patrick A Flume, MD

Patrick A Flume, MD

Professor of Medicine and Pediatrics

Medical University of South Carolina

Powers-Huggins Endowed Chair for Cystic Fibrosis

Charleston, South Carolina

Shannon Kasperbauer, MD

Shannon Kasperbauer, MD

Associate Professor of Medicine

Department of Medicine

Division of Mycobacterial & Respiratory Infections

National Jewish
Denver, Colorado

Mehdi Mirsaeidi, MD, MPH

Mehdi Mirsaeidi, MD, MPH

Director of University of Miami and VA Sarcoidosis Programs

Co-Director UM NTM Program

University of Miami, Miller School of Medicine

Miami, Florida

Julie V. Philley, MD

Julie V. Philley, MD

Chair of the Department of Medicine

Chief of Pulmonary and Critical Care

UT Health North Campus Tyler

The University of Texas Health Sciences Center
Houston, Texas

Stephen Ruoss, MD

Stephen Ruoss, MD

Clinical Chief, Pulmonary and Critical Care Medicine Division

Department of Medicine

Medical Director, Stanford Medical Center Respiratory Care Services

Stanford University Medical Center
Stanford, California

ABOUT THIS PROGRAM AND FACULTY DISCLOSURES

MAC LUNG DISEASE RESOURCES AND TRIALS

Course Videos

Showing 1 - 12 of 89 results

Previous| 1 | 2 | 3 | 4 | 5 ...8 |Next

What is the spectrum of NTM disease in the U.S., especially in patients with underlying lung disease?

What is the spectrum of NTM disease in the U.S., especially in patients with underlying lung disease?

What are the characteristics and/or risk factors that predispose patients to MAC lung infection? And what species are particularly relevant and widespread causative pathogens in NTM lung disease?

What are the characteristics and/or risk factors that predispose patients to MAC lung infection? And what species are particularly relevant and widespread causative pathogens in NTM lung disease?

Why we do need a heightened index of suspicion for recognizing patients who may have NTM lung disease? And what have we learned about epidemiology, transmission, biofilm formation, exposure patterns, and clinical signatures for MAC?

Why we do need a heightened index of suspicion for recognizing patients who may have NTM lung disease? And what have we learned about epidemiology, transmission, biofilm formation, exposure patterns, and clinical signatures for MAC?

What are the diagnostic challenges associated with MAC lung disease, the latency period between symptom onset and diagnosis, the disease burden as we understand it; and finally, the geographical distribution of this infection in the United States?

What are the diagnostic challenges associated with MAC lung disease, the latency period between symptom onset and diagnosis, the disease burden as we understand it; and finally, the geographical distribution of this infection in the United States?

What clinical, microbiological, and radiographic triggers do you need in an individual with MAC lung infection to embark on anti-infective treatment? How often do you see patients with NTM disease and how do you make the decision to treat or monitor?

What clinical, microbiological, and radiographic triggers do you need in an individual with MAC lung infection to embark on anti-infective treatment? How often do you see patients with NTM disease and how do you make the decision to treat or monitor?

Are there specific radiographic findings—cavities, diffuse nodules, or expansion of pulmonary nodules—or other triggers in patients with culture-positive MAC lung disease that indicate a need for initiation of antimicrobial therapy?

Are there specific radiographic findings—cavities, diffuse nodules, or expansion of pulmonary nodules—or other triggers in patients with culture-positive MAC lung disease that indicate a need for initiation of antimicrobial therapy?

What strategies—communication about treatment expectations, managing side effects, use of bronchodilators, etc.—do you employ at the front lines of patient management when using amikacin liposome inhalation suspension in MAC lung disease?

What strategies—communication about treatment expectations, managing side effects, use of bronchodilators, etc.—do you employ at the front lines of patient management when using amikacin liposome inhalation suspension in MAC lung disease?

$Once you’ve decided to deploy the FDA-approved amikacin liposome inhaled aerosol suspension in patients with refractory MAC lung disease, how do you use to optimize patient adherence, tolerability and compliance with this treatment?$ Video

Once you’ve decided to deploy the FDA-approved amikacin liposome inhaled aerosol suspension in patients with refractory MAC lung disease, how do you use to optimize patient adherence, tolerability and compliance with this treatment?

What data and experience have been accumulated over time that explain why NTM pulmonary infection has now become recognized as a significant disease problem with a formidable disease burden and unmet therapeutic needs?

What data and experience have been accumulated over time that explain why NTM pulmonary infection has now become recognized as a significant disease problem with a formidable disease burden and unmet therapeutic needs?

Given the complexity, increasing recognition/prevalence and suboptimal understanding of MAC lung disease, can you summarize for us the disease burden, epidemiology, risk factors, and unmet needs for this infectious condition?

Given the complexity, increasing recognition/prevalence and suboptimal understanding of MAC lung disease, can you summarize for us the disease burden, epidemiology, risk factors, and unmet needs for this infectious condition?

What is likely to be the future burden of MAC and NTM lung disease as our populations ages?

What is likely to be the future burden of MAC and NTM lung disease as our populations ages?

Are there proven strategies for preventing NTM lung disease? If so, what are your recommendations?

Are there proven strategies for preventing NTM lung disease? If so, what are your recommendations?

Showing 1 - 12 of 89 results

Previous| 1 | 2 | 3 | 4 | 5 ...8 |Next